{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:50:44Z","timestamp":1780084244107,"version":"3.54.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,29]]},"DOI":"10.7759\/cureus.72608","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:02:13Z","timestamp":1730196133000},"source":"Crossref","is-referenced-by-count":2,"title":["CK5\/6 Expression in Molecular Subtypes of Invasive Ductal Carcinoma"],"prefix":"10.7759","author":[{"given":"Rafeya","family":"Yasin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rooman Ali Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameen","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonaira","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anila","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei S","year":"2021","unstructured":"Lei S, Zheng R, Zhang S, et al.. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021, 41:1183-94. 10.1002\/cac2.12207","journal-title":"Cancer Commun (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7330-z","article-title":"Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004-2025","volume":"19","author":"Zaheer S","year":"2019","unstructured":"Zaheer S, Shah N, Maqbool SA, Soomro NM. Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004-2025. BMC Public Health. 2019, 19:1001. 10.1186\/s12889-019-7330-z","journal-title":"BMC Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin L","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020, 22:61. 10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"ref6","article-title":"Histological and molecular classification of breast cancer: what do we know?","volume":"12","author":"do Nascimento RG","year":"2020","unstructured":"do Nascimento RG, Otoni KM. Histological and molecular classification of breast cancer: what do we know?. Mastology. 2020, 12:1-8.","journal-title":"Mastology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz B","year":"2022","unstructured":"Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022, 14:2569. 10.3390\/cancers14102569","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2019.11.021","article-title":"Molecular classification of breast cancer: a retrospective cohort study","volume":"49","author":"Al-Thoubaity FK","year":"2020","unstructured":"Al-Thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg (Lond). 2020, 49:44-8. 10.1016\/j.amsu.2019.11.021","journal-title":"Ann Med Surg (Lond)"},{"key":"ref9","article-title":"Breast cancer molecular subtypes: from TNBC to QNBC","volume":"6","author":"Hon JD","year":"2016","unstructured":"Hon JD, Singh B, Sahin A, et al.. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016, 6:1864-72.","journal-title":"Am J Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9605439","article-title":"Global increase in breast cancer incidence: risk factors and preventive measures","volume":"2022","author":"Kashyap D","year":"2022","unstructured":"Kashyap D, Pal D, Sharma R, et al.. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022, 2022:9605439. 10.1155\/2022\/9605439","journal-title":"Biomed Res Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jbi\/wbaa110","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists","volume":"3","author":"Johnson KS","year":"2021","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imaging. 2021, 3:12-24. 10.1093\/jbi\/wbaa110","journal-title":"J Breast Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5152\/tjbh.2014.1777","article-title":"Cinical significance of androgen receptor, CK-5\/6, KI-67 and molecular subtypes in breast cancer","volume":"10","author":"Kayahan M","year":"2014","unstructured":"Kayahan M, \u0130diz UO, Gucin Z, Er\u00f6zgen F, Memmi N, M\u00fcsl\u00fcmano\u011flu M. Cinical significance of androgen receptor, CK-5\/6, KI-67 and molecular subtypes in breast cancer. J Breast Health. 2014, 10:201-8. 10.5152\/tjbh.2014.1777","journal-title":"J Breast Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3477-4","article-title":"Cytokeratin 5\/6 and cytokeratin 8\/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population","volume":"11","author":"Hashmi AA","year":"2018","unstructured":"Hashmi AA, Naz S, Hashmi SK, et al.. Cytokeratin 5\/6 and cytokeratin 8\/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. BMC Res Notes. 2018, 11:372. 10.1186\/s13104-018-3477-4","journal-title":"BMC Res Notes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2518-x","article-title":"Characteristics of basal cytokeratin expression in breast cancer","volume":"139","author":"Alshareeda AT","year":"2013","unstructured":"Alshareeda AT, Soria D, Garibaldi JM, Rakha E, Nolan C, Ellis IO, Green AR. Characteristics of basal cytokeratin expression in breast cancer. Breast Cancer Res Treat. 2013, 139:23-37. 10.1007\/s10549-013-2518-x","journal-title":"Breast Cancer Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu Y","year":"2023","unstructured":"Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023, 10:334. 10.1038\/s41597-023-02253-5","journal-title":"Sci Data"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice C","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, et al.. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017, 3:524-48. 10.1001\/jamaoncol.2016.5688","journal-title":"JAMA Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz S","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021, 13:4287. 10.3390\/cancers13174287","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv022","article-title":"Genetics of breast cancer: a topic in evolution","volume":"26","author":"Shiovitz S","year":"2015","unstructured":"Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015, 26:1291-9. 10.1093\/annonc\/mdv022","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan PH","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, et al.. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020, 77:181-5. 10.1111\/his.14091","journal-title":"Histopathology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000509025","article-title":"Histology of luminal breast cancer","volume":"15","author":"Erber R","year":"2020","unstructured":"Erber R, Hartmann A. Histology of luminal breast cancer. Breast Care (Basel). 2020, 15:327-36. 10.1159\/000509025","journal-title":"Breast Care (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki J","year":"2015","unstructured":"Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015, 8:23-31. 10.4137\/CPath.S31563","journal-title":"Clin Med Insights Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat A","year":"2013","unstructured":"Prat A, Cheang MC, Mart\u00edn M, et al.. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013, 31:203-9. 10.1200\/JCO.2012.43.4134","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades F","year":"2014","unstructured":"Ades F, Zardavas D, Bozovic-Spasojevic I, et al.. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014, 32:2794-803. 10.1200\/JCO.2013.54.1870","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat A","year":"2014","unstructured":"Prat A, Carey LA, Adamo B, et al.. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014, 106:dju152. 10.1093\/jnci\/dju152","journal-title":"J Natl Cancer Inst"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database","volume":"95","author":"Plasilova ML","year":"2016","unstructured":"Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016, 95:e4614. 10.1097\/MD.0000000000004614","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25413","article-title":"Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy","volume":"9","author":"Santonja A","year":"2018","unstructured":"Santonja A, S\u00e1nchez-Mu\u00f1oz A, Lluch A, et al.. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018, 9:26406-16. 10.18632\/oncotarget.25413","journal-title":"Oncotarget"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.36","article-title":"Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants","volume":"2","author":"Pareja F","year":"2016","unstructured":"Pareja F, Geyer FC, Marchi\u00f2 C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016, 2:16036. 10.1038\/npjbcancer.2016.36","journal-title":"NPJ Breast Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Badve S","year":"2011","unstructured":"Badve S, Dabbs DJ, Schnitt SJ, et al.. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011, 24:157-67. 10.1038\/modpathol.2010.200","journal-title":"Mod Pathol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55710-w","article-title":"Molecular stratification within triple-negative breast cancer subtypes","volume":"9","author":"Wang DY","year":"2019","unstructured":"Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci Rep. 2019, 9:19107. 10.1038\/s41598-019-55710-w","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/1658-631X.112908","article-title":"Molecular classification of breast cancer: an overview with emphasis on ethnic variations and future perspectives","volume":"1","author":"Shawarby MA","year":"2013","unstructured":"Shawarby MA, Al-Tamimi DM, Ahmed A. Molecular classification of breast cancer: an overview with emphasis on ethnic variations and future perspectives. Saudi J Med Med Sci. 2013, 1:14-9. 10.4103\/1658-631X.112908","journal-title":"Saudi J Med Med Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4920236","article-title":"CK20 and CK5\/6 immunohistochemical staining of urothelial neoplasms: a perspective","volume":"2020","author":"Akhtar M","year":"2020","unstructured":"Akhtar M, Rashid S, Gashir MB, Taha NM, Al Bozom I. CK20 and CK5\/6 immunohistochemical staining of urothelial neoplasms: a perspective. Adv Urol. 2020, 2020:4920236. 10.1155\/2020\/4920236","journal-title":"Adv Urol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3319-4","article-title":"Cytokeratin 5\/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis","volume":"11","author":"Hashmi AA","year":"2018","unstructured":"Hashmi AA, Hussain ZF, Irfan M, Edhi MM, Kanwal S, Faridi N, Khan A. Cytokeratin 5\/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis. BMC Res Notes. 2018, 11:207. 10.1186\/s13104-018-3319-4","journal-title":"BMC Res Notes"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24478","article-title":"Expression of high molecular weight cytokeratin-a novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma","volume":"83","author":"Lu JG","year":"2023","unstructured":"Lu JG, Lo ET, Williams C, Ma B, Sherrod AE, Xiao GQ. Expression of high molecular weight cytokeratin-a novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma. Prostate. 2023, 83:462-9. 10.1002\/pros.24478","journal-title":"Prostate"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030372","article-title":"Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis","volume":"13","author":"Schulmeyer CE","year":"2023","unstructured":"Schulmeyer CE, Fasching PA, H\u00e4berle L, et al.. Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis. Diagnostics (Basel). 2023, 13:372. 10.3390\/diagnostics13030372","journal-title":"Diagnostics (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen TO","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, et al.. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10:5367-74. 10.1158\/1078-0432.CCR-04-0220","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2015.04.006","article-title":"Prevalence of molecular subtypes of invasive breast cancer: a retrospective study","volume":"71","author":"Kumar N","year":"2015","unstructured":"Kumar N, Patni P, Agarwal A, Khan MA, Parashar N. Prevalence of molecular subtypes of invasive breast cancer: a retrospective study. Med J Armed Forces India. 2015, 71:254-8. 10.1016\/j.mjafi.2015.04.006","journal-title":"Med J Armed Forces India"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.21276\/AABS.2017.1339","article-title":"A comparative study of clinicopathological characteristics and expression of basal markers (CK5\/6 & EGFR) in triple negative and non triple negative breast carcinomas in Kashmir Valley","volume":"25","author":"Khan SP","year":"2017","unstructured":"Khan SP, Yasin SB, Khan FP. A comparative study of clinicopathological characteristics and expression of basal markers (CK5\/6 & EGFR) in triple negative and non triple negative breast carcinomas in Kashmir Valley. Ann Appl Bio-Sci. 2017, 25:35-40. 10.21276\/AABS.2017.1339","journal-title":"Ann Appl Bio-Sci"},{"key":"ref38","article-title":"Identification of different subtypes of breast cancer using tissue microarray","volume":"52","author":"Munirah MA","year":"2011","unstructured":"Munirah MA, Siti-Aishah MA, Reena MZ, et al.. Identification of different subtypes of breast cancer using tissue microarray. Rom J Morphol Embryol. 2011, 52:669-77.","journal-title":"Rom J Morphol Embryol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.36347\/sasjm.2021.v07i05.010","article-title":"Determining the expressions of cytokeratin 5\/6 by immunohistochemistry in basal like triple negative breast carcinoma and its correlation with histomorphological grade","volume":"5","author":"Ara NJ","year":"2021","unstructured":"Ara NJ. Determining the expressions of cytokeratin 5\/6 by immunohistochemistry in basal like triple negative breast carcinoma and its correlation with histomorphological grade. SAS J Med. 2021, 5:204-7. 10.36347\/sasjm.2021.v07i05.010","journal-title":"SAS J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.47009\/jamp.2023.5.5.174","article-title":"Expression of cytokeratin 5\/6 in benign and malignant breast lesions","volume":"5","author":"Sowjanya R","year":"2023","unstructured":"Sowjanya R, Divyagna T, Goud SD, Jyothi C, Swapna B, Kumari KY. Expression of cytokeratin 5\/6 in benign and malignant breast lesions. Int J Acad Med Pharm. 2023, 5:891-6. 10.47009\/jamp.2023.5.5.174","journal-title":"Int J Acad Med Pharm"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11238","article-title":"Expression and clinical significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5\/6, CK17, p53, EGFR, Ki67, p63 in triple-negative breast cancer-a single centre prospective observational study","volume":"32","author":"Constantinou C","year":"2018","unstructured":"Constantinou C, Papadopoulos S, Karyda E, Alexopoulos A, Agnanti N, Batistatou A, Harisis H. Expression and clinical significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5\/6, CK17, p53, EGFR, Ki67, p63 in triple-negative breast cancer-a single centre prospective observational study. In Vivo. 2018, 32:303-11. 10.21873\/invivo.11238","journal-title":"In Vivo"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.36347\/sjams.2015.v03i02.097","article-title":"Breast cancer: correlation of molecular classification with clinicohistopathology","volume":"3","author":"Tiwari S","year":"2015","unstructured":"Tiwari S, Malik R, Trichal VK, et al.. Breast cancer: correlation of molecular classification with clinicohistopathology. Sch J App Med Sci. 2015, 3:1018-26. 10.36347\/sjams.2015.v03i02.097","journal-title":"Sch J App Med Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281422-ck56-expression-in-molecular-subtypes-of-invasive-ductal-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:02:16Z","timestamp":1730196136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281422-ck56-expression-in-molecular-subtypes-of-invasive-ductal-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.72608","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}